PolyPid Ltd. (PYPD) meets investors at the 5th Annual ROTH Healthcare Opportunities Conference, hosted by ROTH Capital Partners at The Metropolitan Club in New York City on Tuesday, September 29, 2026, where B2i Digital is the Marketing Partner. The 5th Annual ROTH Healthcare Opportunities Conference is a B2i Digital Featured Conference. See event details and profiles of participating companies at: https://b2idigital.com/5th-annual-roth-healthcare-opportunities-conference PolyPid Ltd. is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections and has an FDA PDUFA date of November 28, 2026. PolyPid recently signed a commercialization agreement for D-PLEX100 for US and Canada worth over $320M in milestone payments plus double-digit royalties. Credit to the team at ROTH: Byron Roth, Aaron Gurewitz, Isabel Mattson-Pain, Nazan Akdeniz, Otilia "Charo" Montano, Amanda McAdams, James Antonopoulos, Ben Bowen, Kris Salinger, Jason Wittes and Boobalan Pachaiyappan, Ph.D. ROTH built the day around time with management, in a 25-minute 1-on-1 and small group format running from 8:00 AM to 4:30 PM that gives institutional investors extended interaction with the executives running these companies, alongside a keynote. This is an invitation-only event and registration is subject to approval by ROTH. To request registration: https://www.meetmax.com/sched/event_139361/conference_home.html Participating company website: http://www.polypid.com/ Conference features include: • 1-on-1 and small group meetings between executive management and institutional investors, running from 8:00 AM to 4:30 PM • A 25-minute format built for extended interaction with the executives running these companies • Themed panel discussions across biotech, life science tools and diagnostics, and medtech, together with a keynote B2i Digital, The Capital Markets Matchmaker℠, carries each participating company's story From Marketing to Meetings℠, across its media network with a combined monthly audience of more than 330 million and its own community of 1.7 million+ investors and market participants. ROTH is a relationship-driven investment bank focused on serving growth companies and their investors across capital raising, equity research, sales and trading, mergers and acquisitions (M&A) advisory, and corporate access. For more information, visit www.roth.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. #stocks #investing #stocktok
0.0% ERengagement of this clip — above the author's average (0.00%)
top 40%outperforms 60% of the author's clips
99%of the author's average views
